Compare TLS & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TLS | PRQR |
|---|---|---|
| Founded | 1969 | 2012 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 463.8M | 250.7M |
| IPO Year | 2020 | 2014 |
| Metric | TLS | PRQR |
|---|---|---|
| Price | $5.12 | $1.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $7.75 | ★ $8.14 |
| AVG Volume (30 Days) | ★ 1.0M | 658.1K |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $144,400,000.00 | $18,859,556.00 |
| Revenue This Year | $52.27 | N/A |
| Revenue Next Year | $20.44 | $19.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.44 | N/A |
| 52 Week Low | $1.83 | $1.07 |
| 52 Week High | $8.36 | $3.10 |
| Indicator | TLS | PRQR |
|---|---|---|
| Relative Strength Index (RSI) | 38.00 | 40.51 |
| Support Level | $4.97 | $2.03 |
| Resistance Level | $5.22 | $2.31 |
| Average True Range (ATR) | 0.31 | 0.17 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 9.80 | 13.04 |
Telos Corp offers technologically forwarded, software-based security solutions that empower and protect the world's security-conscious organizations against rapidly evolving, sophisticated, and pervasive threats. Its business has two reportable and operating segments namely Security Solutions and Secure Networks. The Security Solutions segment focuses on cybersecurity, cloud, and identity solutions, and the Secure Networks focuses on enterprise security. The company derives maximum revenue from the Security Solutions segment.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.